Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ONCODESIGN
  6. Summary
    ALONC   FR0011766229

ONCODESIGN

(ALONC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
12.8(c) 12.58(c) 12.3(c) 12.4(c) 12.68(c) Last
7 203 6 136 4 939 6 322 4 767 Volume
+2.73% -1.72% -2.23% +0.81% +2.26% Change
More quotes
Financials
Sales 2020 36,5 M 44,1 M 44,1 M
Net income 2020 1,81 M 2,19 M 2,19 M
Net Debt 2020 3,48 M 4,21 M 4,21 M
P/E ratio 2020 47,6x
Yield 2020 -
Sales 2021 34,5 M 41,7 M 41,7 M
Net income 2021 2,10 M 2,54 M 2,54 M
Net Debt 2021 5,94 M 7,19 M 7,19 M
P/E ratio 2021 236x
Yield 2021 -
Capitalization 86,6 M 105 M 105 M
EV / Sales 2020 2,47x
EV / Sales 2021 2,69x
Nbr of Employees 233
Free-Float 50,6%
More Financials
Company
ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. France accounts for 55.3% of net sales. 
More about the company
Ratings of ONCODESIGN
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ONCODESIGN
05/19GLOBAL MARKETS LIVE : Target, Take-Two, Google, KKR, JP Morgan....
01/28ONCODESIGN  : Maintains Its Revenue and Operating Income at €38 Million in 2020 ..
BU
2020ONCODESIGN  : Announces a Share Ownership Plan for All Employees on the Occasion..
BU
2020ONCODESIGN  : Announces Drug Discovery Cooperation With ViraTherapeutics, a Boeh..
BU
2020ONCODESIGN  : Obtains €15.9 Million of Non-dilutive Financing in the Form of a S..
BU
2020ONCODESIGN : First-half 2020 Results
BU
2020ONCODESIGN  : Half-year results
CO
2020ONCODESIGN  : Announces a Capital Increase Reserved for the Company's Management..
BU
2020ONCODESIGN  : 2nd quarter earnings
CO
2020ONCODESIGN  : Reports Its First-half Revenue and a Strong Increase in Its Cash P..
BU
2020ONCODESIGN  : and HitGen Announce a Strategic Partnership in Integrated Drug Dis..
BU
2020ONCODESIGN  : Announces the Creation of its new “Artificial Intelligence&r..
BU
2020ONCODESIGN : Very Strong Improvement in Full-Year 2019 Results
BU
2020ONCODESIGN  : Annual results
CO
2020ONCODESIGN  : to Host Conference Call Following the 2019 Full-Year Results Publi..
BU
More news
News in other languages on ONCODESIGN
05/19STOCK MARKET PARIS : Ça plafonne
05/19EN DIRECT DES MARCHES  : STMicroelectronics, BNP Paribas, JCDecaux, Solutions 30..
05/18ONCODESIGN  : & InterSystems s'allient pour optimiser l'exploitation des données..
04/09ONCODESIGN  : LCM reste à l'Achat
04/09ONCODESIGN  : soutenu par des résultats annuels très solides
More news
Chart ONCODESIGN
Duration : Period :
ONCODESIGN Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCODESIGN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 16,23 €
Last Close Price 12,68 €
Spread / Highest target 57,7%
Spread / Average Target 28,0%
Spread / Lowest Target 6,47%
EPS Revisions
Managers and Directors
NameTitle
Philippe Genne Chairman & Chief Executive Officer
Arnaud Lafforgue Chief Financial & Administrative Officer
Jan Hoflack Chief Scientific Officer
Francis Bichat Director-Technology
Stéphane Gerart Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
ONCODESIGN7.91%105
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416